Edesa Biotech initiated with a Buy at Lucid Capital

Lucid Capital analyst Dev Prasad initiated coverage of Edesa Biotech (EDSA) with a Buy rating and $9 price target The firm has a positive outlook on the company’s lead clinical asset, EB06. EB06 is a first-in-class, fully human monoclonal antibody targeting CXCL10, in development for the treatment of moderate-to-severe non-segmental vitiligo, a chronic autoimmune skin disorder with high unmet medical need, the analyst tells investors in a research note. Lucid says the mechanism of action is well-supported by a strong biological rationale. Lucid views Edesa as an attractive long-term growth opportunity, with a first-in-class asset.